Biotechnology company focused on cellular rejuvenation programming.
Decoding the rejuvenation program of human pluripotent stem cells.
The world's first biomedical research institution exclusively dedicated to research on aging and age-related disease.
Epigenetic testing company focused on aging algorithms.
Clinical-stage biotechnology company mapping molecular pathways of aging to develop therapies for immune aging.
A clinical-stage biotechnology company using generative AI for end-to-end drug discovery and research.
Uses AI to identify safe rejuvenation genes that can reset the epigenetic clock without causing cancer.
A startup with a mission to increase healthy human lifespan by ten years, focusing on cellular reprogramming, autophagy, and plasma-inspired therapeutics.
Consumer health company focused on aging research and supplements.
Multi-omic foundation models for aging clocks are large AI models trained on longitudinal data across multiple biological modalities including DNA methylation (methylome), protein levels (proteome), metabolite levels (metabolome), and clinical data to infer tissue-specific biological age and predict future health trajectories. These comprehensive clocks move beyond single-modality epigenetic clocks (which only use DNA methylation) by integrating multiple types of biological data, enabling more sensitive and accurate measurement of biological aging and the effects of anti-aging interventions, as well as better population stratification in longevity clinical trials where understanding individual aging rates is important.
This innovation addresses the limitation of single-modality aging clocks, where using only one type of data (like DNA methylation) may not capture the full picture of biological aging. By integrating multiple data types, these models can provide more accurate and comprehensive assessments of biological age. Companies and research institutions are developing these advanced aging clocks.
The technology is particularly valuable for longevity research and anti-aging interventions, where accurate measurement of biological age is essential for assessing effectiveness. As the technology improves, it could become a standard tool for aging research and personalized health. However, ensuring accuracy, integrating diverse data types, and understanding what multi-omic biological age means clinically remain challenges. The technology represents an important evolution in aging measurement, but requires continued development to achieve the accuracy and clinical utility needed for widespread use. Success could enable better assessment of aging interventions and personalized health optimization, but the field is still developing and requires more research to understand optimal applications and clinical significance.
